SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke DOI Creative Commons
А. В. Симаненкова,

Oksana Fuks,

Н. В. Тимкина

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2797 - 2797

Published: Dec. 10, 2024

Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity GLP-1RA on brain damage volume neurological status in non-diabetic diabetic rats investigate underlying mechanisms. Methods: Non-diabetic Wistar were divided into five groups (n = 10 each) received empagliflozin, canagliflozin, or dulaglutide as drugs metformin comparison drug. Control animals administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed deficit, neuronal astroglial markers, volume. also modeled type 2 DM using high-fat diet+nicotinamide/streptozotocin method established similar treatment groups. After 8 weeks, subjected further neuroglial necrosis measurement. Results: In rats, all showed an infarct-limiting effect; more effective than metformin. DULA improved compared MET treatment. All decreased neurofilament light chains (NLCs) level none them glial marker S100BB. DM, similarly, had effects. Neurological deficit was most pronounced untreated reduced by drugs. NLC level; None affected neuron-specific enolase. Conclusions: experimental might be conditions it influences both status. decrease damage, while highly selective EMPA, low-selective CANA, impact neuroglia conditions.

Language: Английский

Cognitive Impairment and Synaptic Dysfunction in Cardiovascular Disorders: The New Frontiers of the Heart–Brain Axis DOI Creative Commons
Teresa Soda, Teresa Pasqua, Giovambattista De Sarro

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2387 - 2387

Published: Oct. 18, 2024

Within the central nervous system, synaptic plasticity, fundamental to processes like learning and memory, is largely driven by activity-dependent changes in strength. This plasticity often manifests as long-term potentiation (LTP) depression (LTD), which are bidirectional modulations of efficacy. Strong epidemiological experimental evidence show that heart-brain axis could be severely compromised both neurological cardiovascular disorders. Particularly, disorders, such heart failure, hypertension, obesity, diabetes insulin resistance, arrhythmias, may lead cognitive impairment, a condition known cardiogenic dementia. Herein, we review available knowledge on molecular mechanisms dementia arise describe how LTP and/or LTD induction maintenance CA1 region hippocampus metabolic syndrome, arrhythmias. We also discuss emerging endothelial dysfunction contribute directly altering hippocampal impairing synaptically induced activation nitric oxide synthase. A better understanding CV disorders impact proper function synapses will shed novel light underpinnings dementia, thereby providing new perspective for more specific pharmacological treatments.

Language: Английский

Citations

3
Canagliflozin attenuates neurodegeneration and ameliorates dyskinesia through targeting the NLRP3/Nurr1/GSK-3β/SIRT3 pathway and autophagy modulation in rotenone-lesioned rats DOI

Ahmed M Abdelaziz,

Nora O. Abdel Rasheed,

Hala F. Zaki

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 146, P. 113839 - 113839

Published: Dec. 18, 2024

Language: Английский

Citations

1
Empagliflozin Attenuates High-Glucose-Induced Astrocyte Activation and Inflammation via NF-κB Pathway DOI Creative Commons
Dong Hee Kim, Min Jin Lee, Dasol Kang

et al.

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 46(11), P. 12417 - 12427

Published: Nov. 4, 2024

Sodium-glucose cotransporter-2 (SGLT2) inhibitors regulate blood glucose levels in patients with type 2 diabetes mellitus and may also exert anti-inflammatory anti-atherosclerotic effects by promoting M2 macrophage polarization. Although SGLT2 is expressed brain regions that influence balance cognitive function, its roles the central nervous system are unclear. This study investigated of empagliflozin (EMPA), an inhibitor, on hypothalamic inflammation associated metabolic diseases. Mice were subjected to a high-fat diet (HFD) for varying durations (3 d, 3 weeks, 16 weeks) treated EMPA weeks (NFD, NFD + EMPA, HFD, HFD EMPA;

Language: Английский

Citations

0
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Citations

0
SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke DOI Creative Commons
А. В. Симаненкова,

Oksana Fuks,

Н. В. Тимкина

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2797 - 2797

Published: Dec. 10, 2024

Background: SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) have demonstrated nephro- cardioprotective effects, but their neuroprotective properties, especially concerning stroke severity, mechanisms are not unambiguous. We aimed to study the influence of SGLT-2i with different selectivity GLP-1RA on brain damage volume neurological status in non-diabetic diabetic rats investigate underlying mechanisms. Methods: Non-diabetic Wistar were divided into five groups (n = 10 each) received empagliflozin, canagliflozin, or dulaglutide as drugs metformin comparison drug. Control animals administered 0.9% NaCl for 7 days before stroke. At 48 h after stroke, we assessed deficit, neuronal astroglial markers, volume. also modeled type 2 DM using high-fat diet+nicotinamide/streptozotocin method established similar treatment groups. After 8 weeks, subjected further neuroglial necrosis measurement. Results: In rats, all showed an infarct-limiting effect; more effective than metformin. DULA improved compared MET treatment. All decreased neurofilament light chains (NLCs) level none them glial marker S100BB. DM, similarly, had effects. Neurological deficit was most pronounced untreated reduced by drugs. NLC level; None affected neuron-specific enolase. Conclusions: experimental might be conditions it influences both status. decrease damage, while highly selective EMPA, low-selective CANA, impact neuroglia conditions.

Language: Английский

Citations

0